2196-56-7 Usage
General Description
3-Carboxy-DL-phenylalanine is a synthetic amino acid derivative that contains a carboxylic acid group and consists of equal parts of D-phenylalanine and L-phenylalanine. It is commonly used as a building block in the synthesis of peptides and other complex organic compounds. 3-CARBOXY-DL-PHENYLALANINE has potential applications in the pharmaceutical and biotechnology industries for the production of drugs, as well as in research and development for studying the structure-activity relationships of proteins and enzymes. 3-Carboxy-DL-phenylalanine may also have potential uses in the food and beverage industry for enhancing the nutritional content and flavor of products.
Check Digit Verification of cas no
The CAS Registry Mumber 2196-56-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,1,9 and 6 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 2196-56:
(6*2)+(5*1)+(4*9)+(3*6)+(2*5)+(1*6)=87
87 % 10 = 7
So 2196-56-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H11NO4/c11-8(10(14)15)5-6-2-1-3-7(4-6)9(12)13/h1-4,8H,5,11H2,(H,12,13)(H,14,15)
2196-56-7Relevant articles and documents
New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity
Nakayama, Yoshisuke,Senokuchi, Kazuhiko,Sakaki, Katsuhito,Kato, Masashi,Maruyama, Toru,Miyazaki, Toru,Ito, Hidenori,Nakai, Hisao,Kawamura, Masanori
, p. 971 - 985 (2007/10/03)
A series of new trypsin-like serine protease inhibitors, 1, 2 and 7-23, containing amidinobenzene moiety was found to show potent LTB4-receptor affinity. Among them, compounds 1 and 2 were found to be LTB4 receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB4. Compounds 1 and 2, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB4 receptor antagonist activity, in vivo.